Can a quick strike drug stop MS in its tracks?

NCT ID NCT05418010

Recruiting now Disease control Sponsor: Queen Mary University of London Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving the drug natalizumab (Tyruko) within two weeks of first MS symptoms can help repair nerve damage. Forty adults with a first episode of MS-like inflammation will receive either the drug or a placebo. The main goal is to see if early treatment improves nerve healing on brain scans after 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Natalizumab (Tyruko), a drug that calms the immune system to reduce inflammation in the brain and spinal cord.
What this could lead to: If it works, this could show that starting a strong MS drug very early after first symptoms helps repair nerve damage and leads to better long-term outcomes.
What could go wrong: This is a small, early-phase trial with only 40 people. The drug may not improve nerve repair, and it carries risks like serious brain infections (PML) with long-term use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICALLY ISOLATED SYNDROME OF DEMYELINATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease autoimmune disorder of the nervous system Charcot-Marie-Tooth disease type 1F demyelinating disease immune system disorder multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLINICALLY ISOLATED SYNDROME OF DEMYELINATION MULTIPLE SCLEROSIS

Contacts and locations

Locations

Royal London Hospital
NOT_YET_RECRUITING

London, E1 1FR, United Kingdom
St George's Hospital
RECRUITING

London, SW17 0QT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.